• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.

Jun 11, 2025 | 2025, Events, Investors

Following last night’s announcement regarding OncoACP3, we are pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET. Please contact us at IR@philogen.com or follow the link to register to the...

Deposito del Verbale dell’Assemblea degli Azionisti

May 26, 2025 | 2025, Investors, Press Releases

More details

Il Consiglio di Amministrazione approva la Posizione Finanziaria Netta relativa al Primo Trimestre 2025

May 6, 2025 | 2025, Investors, Press Releases

more details

L’Assemblea degli Azionisti di Philogen S.p.A. si è riunita in data odierna, in sede ordinaria e straordinaria

Apr 29, 2025 | 2025, Investors, Press Releases

more details

Avviso pubblicazione liste per elezione del Consiglio di Amministrazione e altra documentazione relativa all’Assemblea degli Azionisti convocata per il 29 aprile 2025

Apr 7, 2025 | 2025, Investors, Press Releases

more details

Philogen FY 2024 report on April 2, 2025

Apr 2, 2025 | 2025, Investors, Past Events

Philogen is pleased to invite you to an upcoming webinar on April 2, 2025, at 15:00 GMT | 16:00 CET. Click on the link to register or contact us at IR@philogen.com
« Older Entries

Recent Posts

  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • La controllata Philochem AG ha concesso in licenza i diritti a livello mondiale su OncoACP3, un nuovo agente terapeutico e diagnostico per il trattamento del cancro alla prostata, a RayzeBio, società del gruppo Bristol-Myers Squibb, per un valore fino a 1,35 miliardi di dollari più royalties.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
  • The MedChem division of the Italian Chemical Society (SCI) awarded two Prizes to Philochem employees: Samuele Cazzamalli (Head of Chemistry) and Sara Puglioli (Research Scientist)
  • Deposito del Verbale dell’Assemblea degli Azionisti

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it